Constantinos Kurt Wibmer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8296104/publications.pdf

Version: 2024-02-01

31	8,191	394286	414303
papers	citations	19 h-index	32 g-index

37	37	37	12572
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	13.7	1,381
2	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 2021, 384, 1885-1898.	13.9	1,077
3	SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine, 2021, 27, 622-625.	15.2	984
4	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 2022, 602, 654-656.	13.7	928
5	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	13.7	681
6	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 ⁺ T Cell Decline and High Viral Load during Acute Infection. Journal of Virology, 2011, 85, 4828-4840.	1.5	441
7	Evolution of an HIV glycanâ€“dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine, 2012, 18, 1688-1692.	15.2	273
8	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	1.5	205
9	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 2013, 9, e1003738.	2.1	190
10	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. Journal of Virology, 2009, 83, 8925-8937.	1.5	170
11	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. Journal of Virology, 2011, 85, 11502-11519.	1.5	168
12	Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). New England Journal of Medicine, 2021, 384, 2161-2163.	13.9	111
13	HIV broadly neutralizing antibody targets. Current Opinion in HIV and AIDS, 2015, 10, 135-143.	1.5	110
14	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host and Microbe, 2021, 29, 1093-1110.	5.1	73
15	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	1.5	54
16	UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of Human Immunodeficiency Virus Type 1 Subtype C. Journal of Virology, 2012, 86, 4989-4999.	1.5	38
17	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	2.1	33
18	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. Journal of Virology, 2016, 90, 10220-10235.	1.5	32

#	Article	IF	Citations
19	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to Î±4Î²7. PLoS Pathogens, 2018, 14, e1007278.	2.1	29
20	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nature Communications, 2022, 13, 1976.	5.8	27
21	Common helical V1V2 conformations of HIV-1 Envelope expose the Î±4Î²7 binding site on intact virions. Nature Communications, 2018, 9, 4489.	5.8	24
22	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Reports, 2018, 25, 3123-3135.e6.	2.9	23
23	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on Î±4Î²7 for replication. Retrovirology, 2015, 12, 54.	0.9	19
24	Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. Journal of Virology, 2020, 94, .	1.5	15
25	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virology Journal, 2013, 10, 347.	1.4	14
26	The V2 loop of HIV gp120 delivers costimulatory signals to CD4⁺T cells through Integrin Î±₄Î²₇and promotes cellular activation and infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32566-32573.	3.3	14
27	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. Frontiers in Immunology, 2020, 11, 984.	2.2	9
28	Genome Sequencing of a Severe Acute Respiratory Syndrome Coronavirus 2 Isolate Obtained from a South African Patient with Coronavirus Disease 2019. Microbiology Resource Announcements, 2020, 9, .	0.3	8
29	A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathogens, 2022, 18, e1010465.	2.1	8
30	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. Frontiers in Immunology, 2020, 11, 626464.	2.2	4
31	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. AIDS Research and Human Retroviruses, 2014, 30, A20-A21.	0.5	1